Filing Flows › Nektar Therapeutics (NKTR) › Q2 2026
Nektar Therapeutics (NKTR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Nektar Therapeutics (NKTR) reported revenue of $10.1M for the second quarter 2026 (Q2 2026), -9% from a year earlier and -7% from the quarter before. Operating margin was -417.9%, net loss $40.6M (401.0% of revenue).
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.1M | -7% | -9% |
| Operating profit | −$42.3M | — | — |
| Net earnings | −$40.6M | — | — |
| Operating cash flow | −$75.8M | — | — |
What changed
Revenue was $10.1M in Q2 2026, down 9% year over year and down 7% from the previous quarter.
Operating costs exceeded revenue by $42.3M, an operating margin of -417.9%. Total costs grew 11% against a revenue fall of 9%. The fastest-growing cost line was Research & development (+31%). The quarter ended with a net loss of $40.6M, narrower than the previous quarter's $44.9M loss.
Operating cash flow was −$75.8M. Non-cash charges added back $156K of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items used $38.7M. Capital expenditures of $94K exceeded it, leaving free cash flow of −$75.9M.
Questions
What was Nektar Therapeutics' revenue in the second quarter 2026?
Nektar Therapeutics (NKTR) reported revenue of $10.1M for the second quarter 2026 (Q2 2026), -9% from a year earlier and -7% from the quarter before.
Was Nektar Therapeutics profitable in the second quarter 2026?
Operating loss was $42.3M (-417.9% of revenue) and net loss $40.6M.